Current practice of Gleason grading of prostate carcinoma

Virchows Archiv

Volumn 448, Issue 2, 2006, Pages 111-118

  Lopez Beltran, Antonio ^a   Mikuz, Gregor ^b   Luque, Rafael J ^c   Mazzucchelli, Roberta ^d   Montironi, Rodolfo ^d  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c Pathology Department   (Spain)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Gleason grade; Gleason score; Prostate biopsy; Prostate cancer; Radical prostatectomy

Indexed keywords

CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER GROWTH; CELL ULTRASTRUCTURE; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; GLEASON SCORE; HUMAN; MEDICAL SOCIETY; NEEDLE BIOPSY; OBSERVER VARIATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW; SAMPLING ERROR;

HUMANS; MALE; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PROSTATE; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX;

EID: 32544431923     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-005-0102-4     Document Type: Review

References (50)

1. Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 32:74-80
2. Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 32:81-88
3. Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R (2005) Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 216:20-33
4. Amin MB, Grignon DJ, Humphrey PA, Srigley JR (2004) Gleason grading of prostate cancer: a contemporary approach. Lippincott Williams & Wilkins, Philadelphia, PA
5. Amin MB, Schultz DS, Zarbo RJ (1994) Analysis of cribriform morphology in prostatic neoplasia using antibody to high-molecular-weight cytokeratins. Arch Pathol Lab Med 118:260-264
6. Augustin H, Eggert T, Wenske S, Karakiewicz PI, Palisaar J, Daghofer F, Huland H, Graefen M (2004) Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. J Urol 171:177-181
7. Babaian RJ, Troncoso P, Bhadkamkar VA, Johnston DA (2001) Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 91:1414-1422
8. Bailar JC 3rd, Mellinger GT, Gleason DF (1966) Survival rates of patients with prostatic cancer, tumor stage, and differentiation - preliminary report. Cancer Chemother Rep 50:129-136
9. Boccon-Gibod L, van der Kwast TH, Montironi R, Bono A (2004) Handling and pathology reporting of prostate biopsies. Eur Urol 46:177-181
10. Bostwick DG (1994) Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 18:796-803
11. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW (2000) Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:995-1000
12. Chan TY, Partin AW, Walsh PC, Epstein JI (2000) Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 56:823-827
13. Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle R, Gardner TA (2005) The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol 23:2911-2917
14. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) Pathology and genetics. Tumors of the urinary system and male genital organs. IARC, Lyon
15. Egan AJ, Lopez-Beltran A, Bostwick DG (1997) Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. Am J Surg Pathol 21:931-935
16. Egevad L, Allsbrook WC Jr., Epstein JI (2005) Current practice of Gleason grading among genitourinary pathologists. Hum Pathol 36:5-9
17. Epstein JI (2000) Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 24:477-478
18. Epstein JI, Allsbrook WCJ, Amin MB, Egevad LL, and The ISUP Grading Committee (2005) The 2005 International Society of Urological Pathoogy (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228-1242
19. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R (2005) Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl:34-63
20. Epstein JI, Partin AW, Sauvageot J, Walsh PC (1996) Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20:286-292
21. Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50:125-128
22. Gleason DF (1977) Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M (eds) Urologic pathology: the prostate. Lea & Feibiger, Philadelphia, PA
23. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58-64
24. Grober ED, Tsihlias J, Jewett MA, Sweet JM, Evans AJ, Trachtenberg J, Robinette M, Nam RK (2004) Correlation of the primary Gleason pattern on prostate needle biopsy with clinico-pathological factors in Gleason 7 tumors. Can J Urol 11:2157-2162
25. Humphrey PA (2003) Prostate pathology. ASCP Press, Chicago, IL
26. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin KM, Ohori M (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170:1792-1797
27. Kunz GM Jr, Epstein JI (2003) Should each core with prostate cancer be assigned a separate Gleason score? Hum Pathol 34:911-914
28. Lopez-Beltran A, Eble JN, Bostwick DG (2005) Pleomorphic giant cell carcinoma of the prostate. Arch Pathol Lab Med 129:683-685
29. Lopez-Beltran A, Qian J, Montironi R, Luque RJ, Bostwick DG (2005) Atypical adenomatous hyperplasia (adenosis) of the prostate: DNA ploidy analysis and immunophenotype. Int J Surg Pathol 13:167-173
30. Makarov DV, Sanderson H, Partin AW, Epstein JI (2002) Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4+3 and 3+4 independent of the number of involved cores? J Urol 167:2440-2442
31. Mazzucchelli R, Lopez-Beltran A, Scarpelli M, Montironi R (2002) Predictive factors in prostate needle biopsy. Pathologica 94:331-337
32. Mazzucchelli R, Santinelli A, Lopez-Beltran A, Scarpelli M, Montironi R (2002) Evaluation of prognostic factors in radical prostatectomy specimens with cancer. Urol Int 68:209-215
33. Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johnston D, Reyes AO, Babaian RJ (2002) Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 167:1675-1680
34. Mills SE, Fowler JE Jr (1986) Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer 57:346-349
35. Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F (2005) Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 95:1146-1152
36. Montironi R, Mazzucchelli R, Stramazzotti D, Scarpelli M, Lopez Beltran A, Bostwick DG (2005) Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression. J Clin Pathol 58:290-296
37. Montironi R, Mazzucchelli R, van der Kwast T (2003) Morphological assessment of radical prostatectomy specimens. A protocol with clinical relevance. Virchows Arch 442:211-217
38. Montironi R, van der Kwast T, Boccon-Gibod L, Bono AV (2003) Handling and pathology reporting of radical prostatectomy specimens. Eur Urol 44:626-636
39. Montironi R, Scarpelli M, Lopez Beltran A (2004) Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors. Virchows Arch 444:503-508
40. Mosse CA, Magi-Galluzzi C, Tsuzuki T, Epstein JI (2004) The prognostic significance of tertiary Gleason pattern 5 in radical prostatectomy specimens. Am J Surg Pathol 28:394-398
41. Pacelli A, Lopez-Beltran A, Egan AJ, Bostwick DG (1998) Prostatic adenocarcinoma with glomeruloid features. Hum Pathol 29:543-546
42. Pan CC, Chiang H, Chang YH, Epstein JI (2000) Tubulocystic clear cell adenocarcinoma arising within the prostate. Am J Surg Pathol 24:1433-1436
43. Pan CC, Potter SR, Partin AW, Epstein JI (2000) The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol 24:563-569
44. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445-1451
45. Rubin MA, Bismar TA, Curtis S, Montie JE (2004) Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? Am J Surg Pathol 28:946-952
46. Rubin MA, Dunn R, Kambham N, Misick CP, O'Toole KM (2000) Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy? Am J Surg Pathol 24:1634-1640
47. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, Tiguert R, Powell IJ, Wood DP (2000) Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 56:730-734
48. Srigley JR, Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Wheeler TM, Montironi R (2005) Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl 216:8-19
49. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI (1997) Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21:566-576
50. Tran TT, Sengupta E, Yang XJ (2001) Prostatic foamy gland carcinoma with aggressive behavior: clinicopathologic, immunohistochemical, and ultrastructural analysis. Am J Surg Pathol 25:618-623